Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

At this year’s conference, pharmaphorum editor-in-chief Jonah Comstock caught up with Catherine Owen Adams, the CEO of Acadia ...

A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

In his first speech since being appointed Health and Human Services Secretary, Robert F Kennedy Jr pledged to investigate the ...

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of ...

The text of the bill is vanishingly short and does not give any indication of the drugs that might be prescribed by AIs or ...

As a bonus, Bavarian Nordic also gets a priority review voucher from the FDA, awarded as an incentive to carry out drug ...

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...

The company has assembled a team that hails from DeepMind and Microsoft, AI in drug discovery specialist Exscientia, genomics ...